Tuesday, July 22, 2025 | 12:41 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Merck Covid pill gains US clearance for high-risk adults

Molnupiravir, developed by Merck with partner Ridgeback Biotherapeutics LP, is intended to treat Covid in nonhospitalized people 18 and older at risk of developing severe illness

merck, uk covid cases
premium

Fiona Rutherford | Bloomberg
Merck & Co.’s Covid-19 pill was cleared by U.S. regulators, giving high-risk patients another at-home treatment option at a time when the omicron variant is causing cases to surge.
 
The drug, molnupiravir, received emergency authorization on the heels of Pfizer Inc.’s competing pill that was cleared Wednesday, Paxlovid. Together, the treatments promise to provide a new way to keep a sharp rise in infections from overwhelming U.S. hospitals.

Molnupiravir, developed by Merck with partner Ridgeback Biotherapeutics LP, is intended to treat Covid in nonhospitalized people 18 and older at risk of developing severe illness. A study showed it reduced the